{
    "ticker": "HRTX",
    "name": "Heron Therapeutics, Inc.",
    "description": "Heron Therapeutics, Inc. is a biotechnology company dedicated to advancing innovative medicines for patients with unmet medical needs. Founded in 2006 and headquartered in San Diego, California, Heron specializes in the development of new therapies to improve the treatment of acute and chronic pain, as well as for the management of postoperative nausea and vomiting. The company's lead product, Zynrelef (bupivacaine and meloxicam), is a dual-acting local anesthetic approved for the management of postoperative pain, and it represents a significant advancement in pain management by providing long-lasting relief without the side effects associated with opioids. Heron is also working on expanding its pipeline with additional therapies aimed at enhancing patient outcomes and minimizing the risks of existing treatment options. The company is committed to rigorous research and development, ensuring that its products are not only effective but also safe for patients. With a focus on patient-centric solutions, Heron Therapeutics strives to address the challenges faced by healthcare providers and patients in managing pain and nausea effectively.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "San Diego, California, USA",
    "founded": "2006",
    "website": "https://www.herontx.com",
    "ceo": "Barry Quart",
    "social_media": {
        "twitter": "https://twitter.com/HeronTherapeutics",
        "linkedin": "https://www.linkedin.com/company/heron-therapeutics/"
    },
    "investor_relations": "https://investors.herontx.com",
    "key_executives": [
        {
            "name": "Barry Quart",
            "position": "CEO"
        },
        {
            "name": "Michael J. Aisner",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Pain Management",
            "products": [
                "Zynrelef"
            ]
        },
        {
            "category": "Postoperative Care",
            "products": [
                "Sustol"
            ]
        }
    ],
    "seo": {
        "meta_title": "Heron Therapeutics, Inc. | Innovative Pain Management Solutions",
        "meta_description": "Heron Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for pain management and postoperative nausea. Discover our products and commitment to patient care.",
        "keywords": [
            "Heron Therapeutics",
            "Pain Management",
            "Biotechnology",
            "Zynrelef",
            "Postoperative Care"
        ]
    },
    "faq": [
        {
            "question": "What is Heron Therapeutics known for?",
            "answer": "Heron Therapeutics is known for developing innovative therapies for pain management and postoperative nausea."
        },
        {
            "question": "Who is the CEO of Heron Therapeutics?",
            "answer": "Barry Quart is the CEO of Heron Therapeutics, Inc."
        },
        {
            "question": "Where is Heron Therapeutics headquartered?",
            "answer": "Heron Therapeutics is headquartered in San Diego, California, USA."
        },
        {
            "question": "What is Zynrelef?",
            "answer": "Zynrelef is Heron's lead product, a dual-acting local anesthetic approved for postoperative pain management."
        },
        {
            "question": "When was Heron Therapeutics founded?",
            "answer": "Heron Therapeutics was founded in 2006."
        }
    ],
    "competitors": [
        "MYOV",
        "PFE",
        "AMGN",
        "MRK"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "BIIB",
        "VRTX"
    ]
}